Next-Generation Bispecific Nanobody Targeting TFRC and TREM2 for Alzheimer's Disease Intervention

VHH-P837 is an innovative humanized nanobody developed as a bispecific antibody targeting transferrin receptor (TFRC) and triggering receptor expressed on myeloid cells 2 (TREM2). This therapeutic candidate, currently at the Biological Testing stage, has been designed for the potential treatment of Alzheimer's disease. By precisely engaging the extracellular domains of both TFRC and TREM2, VHH-P837 leverages advanced antibody engineering strategies to address key pathological processes in neurodegeneration. The dual-targeting approach supports the rationale for improved disease-modifying activity compared to monotherapies, positioning VHH-P837 as a promising asset in the Alzheimer's disease therapeutic landscape.

Licensing Opportunity

VHH-P837 is currently available for out-licensing and collaborative development. We welcome inquiries from partners interested in advancing this bispecific nanobody program for Alzheimer's disease therapeutics.

Development Phase

Modality

VHH-P837 utilizes a bispecific nanobody format, comprising an agonistic tetra-variable domain immunoglobulin directed at the extracellular domain of human TREM2 and fused with a monovalent single-chain variable fragment targeting TFRC. Built on the robust knobs-into-holes technology, this design confers high structural stability, small molecular size, and excellent tissue penetration—key attributes for traversing the blood-brain barrier and exerting pharmacological action within the central nervous system. The unique format of nanobodies ensures enhanced solubility, manufacturability, and modularity, offering therapeutic advantages in addressing the multifaceted pathology of Alzheimer's disease, particularly where efficient brain delivery and target engagement are critical.

Target

TFRC is a cell surface glycoprotein primarily known for mediating cellular iron uptake, and is broadly expressed on proliferative cells, including those in the blood-brain barrier and neurons. TREM2 is a membrane receptor found predominantly on microglia within the central nervous system, involved in neuroinflammation, immune regulation, and phagocytic activity. Both TFRC and TREM2 play significant roles in Alzheimer's disease progression. Targeting TFRC facilitates efficient brain delivery of therapeutics, while engaging TREM2 modulates microglial activity to counteract neurodegeneration. VHH-P837's simultaneous targeting of TFRC and TREM2 positions it strategically to overcome delivery barriers and harness immune modulation within the Alzheimer’s disease context, optimizing disease-modifying potential and broadening its clinical value.

Mechanism of Action

VHH-P837 exerts its therapeutic action by bispecific engagement of TFRC and TREM2. Through high-affinity binding to TFRC, the molecule utilizes receptor-mediated transcytosis to penetrate the blood-brain barrier, enabling effective delivery to the brain. Concurrently, VHH-P837 agonistically targets TREM2 on microglia, promoting beneficial signal transduction pathways involved in phagocytosis and neuroprotection. As a signal transduction modulator and TREM2 agonist, the nanobody is designed to modify inflammatory status and enhance amyloid-beta clearance. The modularity of this nanobody platform also facilitates future therapeutic expansion, such as in antibody-drug conjugates or novel bispecific constructs, supporting broader applications in neurodegenerative disease treatment.

Alzheimer's Disease

Alzheimer's disease is a progressive and debilitating neurodegenerative disorder, representing the most common cause of dementia worldwide. Characterized clinically by cognitive decline, memory loss, and behavioral changes, it imposes a substantial burden on patients, families, and healthcare systems. Current treatments primarily focus on symptomatic relief via cholinesterase inhibitors or NMDA receptor antagonists, with limited impact on disease progression. Targeted approaches and disease-modifying biologics remain areas of active research, but therapeutic efficacy is often hampered by suboptimal brain delivery and insufficient modulation of neuroinflammatory pathways. There is a critical unmet medical need for innovative interventions that can cross the blood-brain barrier and effectively target pathological mechanisms such as amyloid-beta accumulation and microglial dysfunction. VHH-P837, with its dual targeting of TFRC for enhanced brain penetration and TREM2 for immune activation, holds significant promise as a next-generation treatment to address these therapeutic gaps in Alzheimer's disease management.